DE69129408D1 - 2(5h)- in position 3-substituierte furanone als ca 2+ antagonisten und entzündungshemmende mittel - Google Patents

2(5h)- in position 3-substituierte furanone als ca 2+ antagonisten und entzündungshemmende mittel

Info

Publication number
DE69129408D1
DE69129408D1 DE69129408T DE69129408T DE69129408D1 DE 69129408 D1 DE69129408 D1 DE 69129408D1 DE 69129408 T DE69129408 T DE 69129408T DE 69129408 T DE69129408 T DE 69129408T DE 69129408 D1 DE69129408 D1 DE 69129408D1
Authority
DE
Germany
Prior art keywords
substituted
arylalkyl
alkyl
aryl
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69129408T
Other languages
English (en)
Other versions
DE69129408T2 (de
Inventor
Gary Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DE69129408D1 publication Critical patent/DE69129408D1/de
Publication of DE69129408T2 publication Critical patent/DE69129408T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
DE69129408T 1990-04-17 1991-03-25 2(5h)- in position 3-substituierte furanone als ca 2+ antagonisten und entzündungshemmende mittel Expired - Fee Related DE69129408T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/510,367 US5043457A (en) 1990-04-17 1990-04-17 2(5H)-furanones substituted in the 3 position, as Ca2+ channel antagonists and anti-inflammatory agents
PCT/US1991/002006 WO1991016048A1 (en) 1990-04-17 1991-03-25 2(5H)-FURANONES SUBSTITUTED IN THE 3 POSITION, AS Ca2+ CHANNEL ANTAGONISTS AND ANTI-INFLAMMATORY AGENTS

Publications (2)

Publication Number Publication Date
DE69129408D1 true DE69129408D1 (de) 1998-06-18
DE69129408T2 DE69129408T2 (de) 1998-09-03

Family

ID=24030459

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69129408T Expired - Fee Related DE69129408T2 (de) 1990-04-17 1991-03-25 2(5h)- in position 3-substituierte furanone als ca 2+ antagonisten und entzündungshemmende mittel

Country Status (9)

Country Link
US (1) US5043457A (de)
EP (1) EP0525002B1 (de)
JP (1) JPH05506024A (de)
AT (1) ATE165972T1 (de)
CA (1) CA2078770A1 (de)
DE (1) DE69129408T2 (de)
ES (1) ES2116290T3 (de)
IE (1) IE911266A1 (de)
WO (1) WO1991016048A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5134128A (en) * 1987-06-08 1992-07-28 Allergan, Inc. Anti-inflammatory furanones
US5171863A (en) * 1987-06-08 1992-12-15 Allergan, Inc. Intermediates for preparing 4-substituted 2-5(H)-furanones as anti-inflammatory agents
US5089485A (en) * 1988-11-18 1992-02-18 Allergan, Inc. Anti-inflammatory furanones
US5045564A (en) * 1988-12-07 1991-09-03 Allergan, Inc. Anti-inflammatory 2-furanones
US5258400A (en) * 1989-11-20 1993-11-02 Allergan, Inc. Anti-inflammatory furanone compounds
US5112853A (en) * 1989-11-20 1992-05-12 Allergan, Inc. Anti-inflammatory furanone compounds
US5183906A (en) * 1991-04-30 1993-02-02 Allergan, Inc. 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents
US5225571A (en) * 1991-04-30 1993-07-06 Allergan, Inc. Substituted dihydroxy-bis-[5-hydroxy-2(5H)-furanone-4-yl]-alkanes as anti-inflammatory agents
US5171864A (en) * 1991-08-30 1992-12-15 Allergan, Inc. Di-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega alkane-dioates and N,N-bis-(5-hydroxy-2(5H)-2-oxo-4-furyl)methyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5169963A (en) * 1991-08-30 1992-12-08 Allergan, Inc. Di-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega alkanedioates and N,N-bis-(5-hydroxy-2(5H)2-oxo-4-furyl)alkylmethyl-alpha,omega-dialkanoic acid amides as anti-inflammatory agents
US5268387A (en) * 1992-04-24 1993-12-07 Allergan, Inc. Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss
US5451686A (en) * 1994-04-15 1995-09-19 Allergan, Inc. 3 and 5 alkyl and phenyl 4-(hydroxy or acyloxy)-alkyl substituted 2(5H)-furanones as anti-inflammatory agents
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
WO2004033647A2 (en) * 2002-10-10 2004-04-22 Merck & Co., Inc. Assay methods for state-dependent calcium channel agonists/antagonists
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
US4447455A (en) * 1980-12-01 1984-05-08 Madaus And Company Oral urolithiasis remedy
US4616089A (en) * 1983-08-03 1986-10-07 University Of California Synthetic anti-inflammatory derivatives of manoalide
DE3472958D1 (en) * 1983-08-03 1988-09-01 Univ California Synthetic analgesic and/or anti-inflammatory derivatives of manoalide
JPS6058973A (ja) * 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤
US4789749A (en) * 1984-06-18 1988-12-06 The Regents Of The University Of California Manoalide analogs
ES8707946A1 (es) * 1985-07-01 1987-09-01 Lilly Co Eli Un procedimiento para la preparacion de derivados de furanona.
US4786651A (en) * 1986-02-03 1988-11-22 Allergan, Inc. Treatment of cutaneous hyperproliferative dermatoses with manoalide
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
CA1329390C (en) * 1987-06-08 1994-05-10 John N. Bonfiglio Anti-inflammatory furanones
US4916241A (en) * 1988-06-06 1990-04-10 American Home Products Corporation Inhibition of bone loss by 4-substituted-5-hydroxy-2(5H)-furanones
US4935530A (en) * 1988-10-18 1990-06-19 Allergan, Inc. Process for preparing 5-substituted-3-furaldehydes
US4957917A (en) * 1989-10-25 1990-09-18 Allergan, Inc. Anti-inflammatory furanones
US5013850A (en) * 1990-03-30 1991-05-07 Allergan, Inc. 4-ethyl and 4-ethenyl-5-hydroxy-2(5H)-furanones substituted on alpha carbon of the ethyl or ethenyl side chain with a long chain alkyl group and on the beta carbon with a polar group, as anti-inflammatory agents

Also Published As

Publication number Publication date
ES2116290T3 (es) 1998-07-16
CA2078770A1 (en) 1991-10-18
ATE165972T1 (de) 1998-05-15
IE911266A1 (en) 1991-10-23
DE69129408T2 (de) 1998-09-03
EP0525002A4 (en) 1993-03-10
US5043457A (en) 1991-08-27
WO1991016048A1 (en) 1991-10-31
EP0525002B1 (de) 1998-05-13
EP0525002A1 (de) 1993-02-03
JPH05506024A (ja) 1993-09-02

Similar Documents

Publication Publication Date Title
DE69129408D1 (de) 2(5h)- in position 3-substituierte furanone als ca 2+ antagonisten und entzündungshemmende mittel
MX9305798A (es) Composiciones de lapiz labial humedecedor.
DE69007429D1 (de) Isoindolonderivate, ihre Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
AU557691B2 (en) 2-penem antibiotics and their oxa-aza-, and carba analogues
DE69133299D1 (de) Aminosulfonylcarbamate
TR200001530T2 (tr) Gastrik asit salgılamasının önlenmesi için heterosiklik bileşimler
EA200100139A1 (ru) Фармацевтические композиции, содержащие 2-хинолоны
AU2605784A (en) N-aromatic-n:-cycloalkylalkanoyl-piperazines
NZ332608A (en) alkyl 17-alpha-dichloroacetoxy-11- beta-hydroxy-androsta-1,4-diene-3-one-17-beta-carboxylates and medicaments
ATE69817T1 (de) Tetraoxodiazabicyclo-(3,3,1)-nonane.
FR2663633B1 (fr) Nouvelles chalcones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69801594D1 (de) Kosmetische zusammensetzung enthaltend eine indigotyp-verbindung
DE59002863D1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen.
TR200400857T4 (tr) Yeni galantamın türevleri ve analogları
SE7601143L (sv) Nytt oxadiazolinonderivat
DE3875346D1 (de) Zusammensetzungen, die mit 1-oxo- oder thiokohlenwassserstoff substituierte azacycloalkane enthalten.
ES2070623T3 (es) Oxisulfonilureas inhibidoras de acat.
ATE277031T1 (de) Dihydrobenzofuranderivate verwendbar als entzündungshemmende mittel
ES8404976A1 (es) Procedimiento para preparar nuevos derivados de encefalina.
DE69311123D1 (de) Cyclische benzylamino-, benzylamido- und benzylimido derivate als antipsychotische wirkstoffe
DE69118064D1 (de) Diamino-s-Triazinonderivate und diese enthaltende selbstlöschende polymere Zusammensetzungen
NO983531D0 (no) Dihydrobenzofuranforbindelser anvendelig som antiinflammatoriske midler
FR2658821B1 (fr) Nouvelles propanamines, leurs proprietes pharmacologiques et leur application a des fins therapeutiques, notamment antidiarrheuiques.
ES2043068T3 (es) Utilizacion de diorganopolisiloxanos modificados como anti-oxidantes en cosmetica o dermatologia.
MX9603199A (es) Antagonistas de receptores a endotelina.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee